A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Public ClinicalTrials.gov record NCT06077760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Study identification
- NCT ID
- NCT06077760
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 868 participants
Conditions and interventions
Conditions
Interventions
- Intismeran autogene Biological
- Pembrolizumab Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2023 (Actual)
- Primary completion
- Jun 25, 2030 (Estimated)
- Completion
- Dec 21, 2035 (Estimated)
- Last update posted
- Sep 18, 2026
2023 – 2035
United States locations
- U.S. sites
- 68
- U.S. states
- 29
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology ( Site 0039) | Anchorage | Alaska | 99508 | — |
| The University of Arizona Cancer Center - North Campus ( Site 0071) | Tucson | Arizona | 85719 | — |
| YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020) | Yuma | Arizona | 85364 | — |
| UCLA Clinical & Translational Research Center (CTRC) ( Site 0059) | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian ( Site 4042) | Newport Beach | California | 92663 | — |
| Hoag Memorial Hospital Presbyterian ( Site 4048) | Newport Beach | California | 92663 | — |
| St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074) | Orange | California | 92868 | — |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030) | Orange | California | 92868 | — |
| UCHealth Memorial Hospital-Heme Onc ( Site 0052) | Colorado Springs | Colorado | 80909 | — |
| George Washington University Medical Faculty Associates ( Site 4064) | Washington D.C. | District of Columbia | 20037 | — |
| Mayo Clinic Florida ( Site 4043) | Jacksonville | Florida | 32224 | — |
| Miami Cancer Institute at Baptist Health, Inc. ( Site 4047) | Miami | Florida | 33176 | — |
| Mid Florida Hematology and Oncology Center ( Site 0014) | Orange City | Florida | 32763 | — |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013) | Orlando | Florida | 32804 | — |
| Moffitt Cancer Center ( Site 0078) | Tampa | Florida | 33612 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012) | Marietta | Georgia | 30060 | — |
| Southeastern Regional Medical Center ( Site 0098) | Newnan | Georgia | 30265 | — |
| Beacon Cancer Care ( Site 0044) | Post Falls | Idaho | 83854 | — |
| Illinois Cancer Care ( Site 7003) | Peoria | Illinois | 61615 | — |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 0062) | Iowa City | Iowa | 52242 | — |
| Saint Elizabeth Healthcare ( Site 0092) | Edgewood | Kentucky | 41017 | — |
| The University of Louisville, James Graham Brown Cancer Center ( Site 0037) | Louisville | Kentucky | 40202 | — |
| LSU Health Baton Rouge North Clinic ( Site 4040) | Baton Rouge | Louisiana | 70805 | — |
| Our Lady of the Lake ( Site 4050) | Baton Rouge | Louisiana | 70808 | — |
| University of Michigan Clinical Trials Office ( Site 0058) | Ann Arbor | Michigan | 48109 | — |
| Cancer and Hematology Centers of Western Michigan ( Site 4003) | Grand Rapids | Michigan | 49503 | — |
| St. Vincent Frontier Cancer Center ( Site 0043) | Billings | Montana | 59102 | — |
| NHO Revive Research Institute, LLC ( Site 4009) | Lincoln | Nebraska | 68506 | — |
| Memorial Sloan Kettering - Basking Ridge ( Site 4056) | Basking Ridge | New Jersey | 07920 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0036) | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering - Monmouth ( Site 4057) | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering - Bergen ( Site 4059) | Montvale | New Jersey | 07645 | — |
| Atlantic Health Morristown Medical Center ( Site 4018) | Morristown | New Jersey | 07960 | — |
| New York Oncology Hematology, P.C. ( Site 4012) | Albany | New York | 12206 | — |
| Memorial Sloan-Kettering Cancer Center at Commack ( Site 4055) | Commack | New York | 11725 | — |
| Memorial Sloan Kettering - Westchester ( Site 4058) | Harrison | New York | 10604 | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095) | Mineola | New York | 11501 | — |
| The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 4053) | New York | New York | 10011 | — |
| Laura and Isaac Perlmutter Cancer Center ( Site 0010) | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai ( Site 0034) | New York | New York | 10029 | — |
| Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 0054) | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0029) | New York | New York | 10065 | — |
| Stony Brook University-Cancer Center ( Site 0072) | Stony Brook | New York | 11794 | — |
| Montefiore Medical Center- Montefiore Medical Park-Oncology ( Site 0080) | The Bronx | New York | 10461 | — |
| Memorial Sloan Kettering - Nassau ( Site 4060) | Uniondale | New York | 11553 | — |
| Novant Health Weisiger Cancer Insititute ( Site 4052) | Charlotte | North Carolina | 28204 | — |
| Novant Health Oncology Specialists ( Site 4045) | Winston-Salem | North Carolina | 27103 | — |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0063) | Fargo | North Dakota | 58102 | — |
| Altru Health System ( Site 0040) | Grand Forks | North Dakota | 58201 | — |
| Summa Health ( Site 4011) | Akron | Ohio | 44304 | — |
| University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0028) | Cincinnati | Ohio | 45220 | — |
| University Hospitals Cleveland Medical Center ( Site 0023) | Cleveland | Ohio | 44106 | — |
| OSU Brain and Spine Hospital ( Site 0016) | Columbus | Ohio | 43210 | — |
| Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0082) | Corvallis | Oregon | 97330 | — |
| Thomas Jefferson University - Clinical Research Institute ( Site 0006) | Philadelphia | Pennsylvania | 19107 | — |
| Medical University of South Carolina-Hollings Cancer Center ( Site 0050) | Charleston | South Carolina | 29425 | — |
| Sanford Cancer Center ( Site 0075) | Sioux Falls | South Dakota | 57104 | — |
| Greco-Hainsworth Centers for Research ( Site 4034) | Chattanooga | Tennessee | 37421 | — |
| Thompson Cancer Survival Center ( Site 0097) | Knoxville | Tennessee | 37916 | — |
| Baptist Cancer Center ( Site 4049) | Memphis | Tennessee | 38120 | — |
| One Oncology - Tennessee Oncology ( Site 4019) | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners ( Site 7001) | Nashville | Tennessee | 37203 | — |
| UT Southwestern Medical Center ( Site 0061) | Dallas | Texas | 75390 | — |
| Inova Schar Cancer Institute ( Site 0003) | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Specialists (VCS) ( Site 4004) | Fairfax | Virginia | 22031 | — |
| Swedish Medical Center-Swedish Cancer Institute ( Site 0088) | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Center ( Site 0002) | Seattle | Washington | 98109 | — |
| Edwards Comprehensive Cancer Center ( Site 4015) | Huntington | West Virginia | 25701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 161 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06077760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06077760 live on ClinicalTrials.gov.